SRES-786-119
Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent. (consideration: CR S3052; text: CR S3061-3062)
Sponsored by Lindsey Graham (R-SC)
What it does
This resolution designates July 15, 2026, as "Glioblastoma Awareness Day." It encourages public awareness of glioblastoma, honors patients and those who have died from the disease, and expresses Senate support for research, biomarker testing, and collaboration among government, private, and nonprofit organizations. It does not appropriate funds, create new programs, or impose any legal obligations.
Who benefits
Glioblastoma patients (estimated 13,000+ newly diagnosed in 2026) and their families, caregivers, and advocates who may gain increased public visibility for the disease. Nonprofit brain tumor research organizations that may see increased donations or public engagement. Researchers working on glioblastoma therapies, including those affiliated with the National Cancer Institute's Glioblastoma Therapeutics Network, who may benefit from heightened awareness of funding needs.
Who is hurt
No group is directly harmed by this resolution. There are no mandates, spending changes, or regulatory effects. Opportunity cost critics might note that Senate floor time is a finite resource, but this resolution passed by unanimous consent with no recorded opposition.
Supporters argue
Supporters argue that glioblastoma carries a devastating 7% five-year survival rate and a median survival of only 8 months, yet only 5 drugs and 1 medical device have received FDA approval to treat it since the 1920s — reflecting a severe research gap relative to the disease's lethality. They contend that awareness designations help direct public attention, philanthropic resources, and legislative focus toward underfunded conditions, and note the resolution passed with broad bipartisan support across both parties.
Opponents argue
Opponents might argue that symbolic resolutions consume legislative bandwidth without producing measurable outcomes — no funding is authorized, no research is mandated, and no policy changes result. They contend that if Congress genuinely prioritized glioblastoma, it would direct appropriations to the National Cancer Institute or streamline FDA approval pathways, rather than passing a non-binding awareness designation that imposes no obligations on any actor.